The FDA allows ViroPharma (VPHM +6.5%) to restart clinical trials of the subcutaneous injection...


The FDA allows ViroPharma (VPHM +6.5%) to restart clinical trials of the subcutaneous injection of its Cinryzed drug in combination with rHuPH20, a platform for administering medicines in this way. The agency believes "safety signals" regarding antibodies to rHuPH20 detected in another company's product development are limited to that product's program. Partner Halozyme (HALO) +29%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs